



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

## **Patient Organisation Agreement**

This Patient Organisation Agreement has been drawn up and entered into as of 06 April 2023 by and between

**CSL Behring AB**, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

and

**Danmarks Bløderforening**, Blekinge Boulevard 2, DK-2630 Taastrup, Danmark  
dbf@bloderforeningen.dk

### **1. Background**

The purpose of this agreement is to contribute to the development of the association and to mutual exchange of experience with the Danish Society for Bleeding in Denmark, as well as to support the association's activities in Denmark.

### **2. Collaboration project**

Danmarks Bløderforenings årsmøde April 15-16th 2023, Kobæk Strand

CSL Behring will support the meeting with 30.948 DKK and will be able to include 1-2 materials in the meeting. 4 representatives from CSL Behring can attend the meeting.

Patient survey "Women in bleeding families", April to June 2023

CSL Behring and Danmarks Bløderforening is currently discussing to conduct a survey among women in families with bleeding disorders. The aim of this survey would be to obtain more information about bleeding disorders in women and to assess whether better information and support is needed. If agreed, CSL Behring will prepare the questionnaire, collect and analyze data and compile the results and Danmarks Bløderforening will review and provide input to the content of the questionnaire and will further send out an invitation to the survey to members in the organization, announce and distribute the invitation on social medias and on the website. In that case, a steering group with representatives from the organisation and CSL Behring will be set up to discuss results. CSL Behring will own the data and results will be made available to the organization. Any communication about the results (written or verbally) can only be done after consolidation with CSL Behring. Costs for conduction of the survey study will be covered by CSL Behring.

### **3. Finances**

3.1 CSL Behring AB has undertaken to finance Danmarks Bløderforenings årsmøde with 30.948 DKK. Payment shall be made against separate invoice. The invoice shall be sent to DanderydPayables@cslbehring.com. Costs for conduction of the survey study are covered by CSL Behring.

State Caroline Tegnér as reference on the invoice.

### **4. Transparency**



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

- 4.1 Both Parties consent to the contents of this Agreement being shared with a third party.
- 4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI in accordance with § 3 of the Patient Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI.

## **5. Consultation, evaluation**

- 5.1 Danmarks Bløderforening has appointed Karen Binger Holm as their contact person in matters concerning this Agreement.
- 5.2 CSL Behring AB has appointed Tove Andersson as their contact person in matters concerning this Agreement.
- 5.3 After completion of the project, the Parties shall jointly evaluate the projects in p.2 and their collaboration in relation to these projects.

## **6. Agreement period and early termination**

- 6.1 This Agreement is valid from 6/4/2023 until 31/12/2023.
- 6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

## **7. Ethical rules and law**

- 7.1 Ethical rules and national law apply to this agreement. Danmarks Bløderforening warrants that it will only use the funds received in accordance with national law and the Pharmaceutical Industry's Code of Ethics.
- 7.2 Danmarks Bløderforening may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. Danmarks Bløderforening shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.

## **8. Disputes**

If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.

## **9. E-signature**


The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden


-----  
This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Place and Date: 6.4.2023  
**CSL Behring AB:**

DocuSigned by:  
  
.....A2BDF6F9C6A6498.....

Name and title:  
Tove Andersson, Digital Marketing  
& Patient Advocacy Lead

Place and Date: Danderyd 06/04/2023  
**CSL Behring AB:**

DocuSigned by:  
  
.....39ACB73D6000466.....

Name and title:  
Aymeric Ange  
General Manager

Place and Date: 6.4.2023  
**Danmarks Bløderforening:**

DocuSigned by:  
  
.....A26DBA24CEFB4B1.....

Name and title:  
Karen Binger Holm  
Sekretariatsleder